Completion of the Phase III study
12 February 2021
The phase III study has been completed and the final report of the study on the evaluation of the efficacy and safety of the drug used in the treatment of attention deficit hyperactivity disorder (ADHD) has been prepared in children 6−12 years of age with different dosage regimens.